This page shows how Zepbound coverage works across major insurers, what prior authorization typically requires, and what changes are coming in 2026. Compare coverage across BCBS, UnitedHealthcare, Aetna, Cigna, Medicare, Medicaid, TRICARE, and more.
COVERAGE OVERVIEW
The Short Answer
Short answer: Yes—but coverage varies by plan. Large employer plans are most likely to cover Zepbound with prior authorization. Many marketplace plans exclude weight-loss drugs, and basic Medicare Part D coverage excludes drugs used for weight loss; Medicare covers the Zepbound KwikPen for weight loss only through the Medicare GLP-1 Bridge, a separate CMS program outside Part D (with conditions, including prior authorization).
- ✓ Most large employer plans may cover Zepbound with prior authorization
- ✗ Many ACA marketplace plans exclude it for weight loss; Medicare covers it for weight loss only through the GLP-1 Bridge
- ✓ Coverage may still be possible through appeals or the OSA (sleep apnea) indication
Best for: Employer plans, ACA marketplace, Medicare, Medicaid, TRICARE.
The best price for Zepbound is as little as $25/fill ⚠️ requires insurance coverage
With commercial coverage, the savings card can bring a fill to as little as $25 (savings are capped at $100 per 1-month fill), which can be far less than LillyDirect cash pricing ($299–$449/month). Denied? You can appeal, and 65%+ succeed.
Haven't applied for coverage?
Use the insurer directory below to see how your plan handles Zepbound.
Jump to insurer directory ↓Then find your fastest path to approval →Denied Zepbound coverage?
65%+ of appeals succeed with proper documentation.[5] Don't give up.
Get help with your appeal →✓ Free case review · ✓ Coverage can cost far less than LillyDirect cash pricingKey Coverage Facts
- Employer coverage depends on firm size: GLP-1s for weight loss were covered by 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) (KFF Employer Health Benefits Survey)[2][14]
- Plans that cover Zepbound for weight loss require prior authorization in the insurer policies we checked (UnitedHealthcare, Cigna, Aetna)—your doctor must get approval before you can fill it[1]
- Medicare: Basic Medicare Part D coverage excludes drugs used for weight loss, but the separate Medicare GLP-1 Bridge covers the Zepbound KwikPen for $50 per monthly fill (with conditions); Part D may also cover Zepbound for sleep apnea
- 13 states (as of January 2026): state Medicaid programs that cover GLP-1s for obesity, with policies evolving. The CMS BALANCE model's Medicaid track is Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed[9]
Coverage by Plan Type
| Plan Type | Coverage | Key Notes |
|---|---|---|
| Large employer (5,000+) | Most likely | 43% of firms cover GLP-1s for weight loss (2025); PA required |
| Mid-size employer (200–999) | Less likely | 16% of firms cover GLP-1s for weight loss (2025) |
| ACA Marketplace | Varies | Many plans exclude weight-loss drugs; varies by state and plan |
| Medicare Part D | Bridge only | Basic Medicare Part D coverage excludes drugs used for weight loss; the Medicare GLP-1 Bridge, a separate program outside Part D, covers the Zepbound KwikPen for $50 per monthly fill (with conditions) |
| Medicaid | Varies by state | 13 states (as of January 2026) cover for weight loss; no state confirmed in BALANCE yet |
If Denied, You Can Appeal
Over 65% of prior authorization appeals succeed when patients appeal—yet only about 1 in 10 patients ever file an appeal.[5] If your Zepbound coverage is denied, don't give up. See what to do after a denial →
Looking for Step-by-Step Help?
This page shows which insurers cover Zepbound. For guidance on how to navigate PA, appeals, and get approved, see our How to Get Zepbound Covered by Insurance.
Bottom line: Don't assume your plan covers or excludes Zepbound. Call your insurer to verify, and if denied, remember that you can appeal. Next step: Look up how your insurer handles coverage below.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Insurer Directory
Find Your Insurance Company
Select your insurer below to see coverage policies, prior authorization requirements, and tips for getting approved.
Coverage Changes Frequently
Insurance formularies update regularly. Always verify current coverage with your plan or check the linked pages for the latest specifics.
Blue Cross Blue Shield
Varies by StateCoverage varies significantly by state and plan. When covered, PA typically requires BMI (Body Mass Index) ≥30 or ≥27 + comorbidity and documented lifestyle changes.
View BCBS Coverage →UnitedHealthcare / OptumRx
Plan-DependentDepends on your employer’s plan. When covered, UHC requires PA (BMI ≥30, or ≥27 with a weight-related condition) as an adjunct to lifestyle changes; initial approval for Zepbound is 6 months.
View UHC Coverage →Aetna
PA RequiredPrior authorization required. Aetna's standard criteria require BMI documentation and at least 6 months in a weight-management program; they don't require trying another drug first. Your plan may differ.
View Aetna Coverage →Cigna / Express Scripts
PA RequiredPrior authorization required with state variations. Check if Zepbound is preferred or non-preferred on your specific formulary.
View Cigna Coverage →CVS Caremark
Preferred again Oct 2026Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), after being nonpreferred or excluded on some of its most common commercial formularies from July 1, 2025 to September 30, 2026. Plan sponsors can customize formularies, so check your plan.
View CVS Caremark Coverage →Anthem Blue Cross
Varies by PlanCoverage varies by state and plan type. Some commercial plans exclude GLP-1s for weight loss; some employer plans cover with PA. Always verify your specific formulary.
View Anthem Coverage →Kaiser Permanente
Very LimitedCoverage of Zepbound for weight loss depends on your Kaiser region and your (or your employer's) plan. Check your Kaiser formulary and plan documents.
View Kaiser Coverage →Humana
Medicare & MedicaidHumana no longer sells employer-group commercial medical plans (exit completed in 2025). Humana Medicare drug plan members can use the Medicare GLP-1 Bridge for the Zepbound KwikPen. Medicaid varies by state.
View Humana Coverage →ACA Marketplace Plans
State-DependentCoverage varies by plan and state. ACA plans follow state mandates and insurer policies. Many require PA; some exclude weight loss drugs.
View Marketplace Coverage →Medicare Part D
Bridge liveBasic Medicare Part D coverage excludes drugs used for weight loss, but the separate Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Zepbound KwikPen for $50 per monthly fill with conditions, including prior authorization. Part D may cover the OSA indication, subject to the plan's formulary and prior authorization.
View Medicare Details →Medicaid
Varies by State13 states (as of January 2026) cover GLP-1s for weight loss under fee-for-service Medicaid. BALANCE's Medicaid track is voluntary; no participating state has been confirmed.
View Medicaid Coverage →TRICARE
Plan-DependentPrime & Select may cover with PA + step therapy (trying cheaper drugs first). Coverage varies by plan type. Active duty typically pays $0 copay when covered.
View TRICARE Coverage →Alternative: Sleep Apnea (OSA) Coverage Pathway
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This opens a separate coverage pathway:
- Medicare Part D may cover Zepbound for moderate-to-severe OSA, subject to the plan's formulary, prior authorization and exceptions process (basic Part D still excludes weight loss)
- Some commercial plans cover the OSA indication even when weight loss is excluded (UnitedHealthcare, for example, has a separate Zepbound OSA policy)
Other Plans
What if My Insurer Isn't Listed?
If your insurance company isn't listed above, here's what to do:
Check Your Formulary
Look up "Zepbound" or "tirzepatide" on your plan's formulary (drug list). This tells you if it's covered and at what tier.
Call Your PBM
Your pharmacy benefit manager—the company that manages drug coverage for your insurer (phone number is on your prescription card)—can confirm coverage, PA requirements, and step therapy rules.
Review Your SPD
Your Summary Plan Description (the legal document explaining your benefits) lists all exclusions. Search for "obesity," "weight loss," or "anti-obesity medications."
Self-Funded Employer Plans
If your employer self-funds their health plan (pays claims directly instead of through an insurer), they have broad discretion over drug coverage (state coverage mandates generally don't apply). Your plan may cover Zepbound even if the insurer's standard plans don't—or vice versa. Contact HR or your benefits administrator.
Related Guides
Explore Other Zepbound Coverage Resources
Need more than just insurer-specific info? These guides cover the full coverage landscape.
COVERAGE OUTLOOK
What's Changing in 2026
2026: Diverging Trends
The insurance landscape for Zepbound is splitting: Medicare now has the GLP-1 Bridge while some commercial plans are pulling back. Here's what to watch.
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Government Programs: What's Changing
NEW: TrumpRx.gov (Launched Feb 2026)
TrumpRx.gov launched February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price)—available to all Americans paying cash, regardless of insurance status:
- Zepbound price: the LillyDirect self-pay vial price, $299–$449/month by dose; orders go through LillyDirect
- Who can use it: Anyone—not limited to Medicare/Medicaid
- Best for: people who don't qualify for the Medicare GLP-1 Bridge, the uninsured, or those with non-covering plans
NEW: CMS BALANCE Model (Announced Dec 2025)
On December 23, 2025, CMS announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth)—a voluntary model to expand GLP-1 access through negotiated pricing:[7]
- Medicaid: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
- Medicare Part D: Delayed, with no new start date
- Medicare GLP-1 Bridge (a separate program): live July 1, 2026 – December 31, 2027; Part D enrollees who meet CMS's criteria and get prior authorization pay $50 per monthly fill, outside the Part D benefit
- How it works: CMS negotiates directly with manufacturers for lower net prices; participation is voluntary for states
Check CMS.gov/BALANCE for updates.
Medicare Part D: Current Status
By federal statute, basic Medicare Part D coverage still excludes drugs used for weight loss (some enhanced plans could offer them as supplemental benefits); the Medicare GLP-1 Bridge is a separate, temporary CMS program that runs outside the Part D benefit. The Treat and Reduce Obesity Act has not been enacted.
- OSA pathway: Zepbound may be covered under Part D for moderate-to-severe obstructive sleep apnea in adults with obesity, subject to the plan's formulary, prior authorization and exceptions process
- Part D out-of-pocket cap: $2,100 in 2026 ($2,400 in 2027) for covered Part D drugs[8]
- Weight loss: The Medicare GLP-1 Bridge is live (July 1, 2026 – December 31, 2027) and covers the Zepbound KwikPen for $50 per monthly fill for eligible beneficiaries
Medicaid Coverage: State-by-State
13 states (as of January 2026) explicitly cover at least one GLP-1 for weight management under fee-for-service Medicaid; GLP-1s for type 2 diabetes are covered separately.[4]
- California (Medi-Cal): Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026. A prior authorization can still be requested for Wegovy for cardiovascular disease or Zepbound for sleep apnea, and members under 21 can still get coverage with an approved PA (EPSDT).[10]
- BALANCE Model: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
Verify coverage directly with your state Medicaid program, as policies change frequently.
Commercial Insurance: Tightening Coverage
Many Plans Dropping or Restricting Coverage (Jan 2026)
Effective January 1, 2026, some insurers dropped or restricted GLP-1 coverage for weight loss, limiting it to type 2 diabetes or plans with explicit weight management benefits:[11]
- Health New England: Health New England stopped covering Saxenda, Wegovy and Zepbound for weight loss for Individual and Small Group members on January 1, 2026 (large groups at renewal unless the employer buys a rider)
- Fallon Health: Fallon Health’s Community Care plans stopped covering weight-loss medications on January 1, 2026
- Blue Cross Blue Shield of Massachusetts: Blue Cross Blue Shield of Massachusetts excludes Saxenda, Wegovy and Zepbound from January 1, 2026
- CVS Caremark: From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize)[12]
Self-funded employers can still negotiate to include Zepbound coverage—check with your HR or benefits administrator about your specific plan.
Employer Coverage Trends
Despite cost concerns, most large employers with existing GLP-1 coverage plan to continue it:
- About 90% of large employers currently covering GLP-1s plan to maintain coverage in 2026, according to employer surveys reported by HR Executive[13]
- 44% of employers with 500+ employees covered weight loss medications in 2024, up from prior years (Mercer)[14]
- 64% of employers with 20,000+ employees offered coverage in 2024—the largest employers are most likely to cover[14]
- Cost impact: Covering GLP-1s may increase employer premiums by ~5–14%, driving some to add restrictions[15]
Note: All 2026 timelines, pricing, and coverage expansions are subject to federal rulemaking, final CMS implementation, and individual state/employer decisions. Verify with your specific plan.
What Should You Do Now?
- Verify your 2026 benefits: During open enrollment, confirm whether your employer plan will cover Zepbound next year
- Consider plan switching: If your current plan is dropping coverage, evaluate other options during open enrollment
- Medicare patients: Check whether you qualify for the Medicare GLP-1 Bridge ($50 per monthly fill for the Zepbound KwikPen, with conditions); with moderate-to-severe sleep apnea, your Part D plan may cover Zepbound instead, subject to its formulary and prior authorization
- Explore OSA pathway: If you have sleep apnea symptoms, the OSA indication may provide coverage even when weight loss is excluded
- Need financial help? Zepbound savings and assistance options: with commercial coverage, the savings card can bring a fill to as little as $25. Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list, so there is no free Zepbound program
ZEPBOUND INSURANCE COVERAGE
Frequently Asked Questions
Large employer plans are most likely to cover Zepbound with prior authorization—43% of firms with 5,000+ workers covered GLP-1s for weight loss in 2025 (KFF), and Mercer found 64% of employers with 20,000+ employees did in 2024. Some BCBS, UHC, Aetna, and Cigna plans also cover it depending on your specific plan. Many marketplace plans exclude it for weight loss; Medicare covers the Zepbound KwikPen for weight loss only through the Medicare GLP-1 Bridge ($50 per monthly fill, with conditions). The sleep apnea indication can provide an alternative path to coverage.
Your best bet is a large employer plan. In 2025, GLP-1s for weight loss were covered by 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) (KFF). Per Mercer, 64% of employers with 20,000+ employees offered coverage in 2024. Marketplace plans rarely cover it for weight loss; Medicare covers the Zepbound KwikPen for weight loss only through the Medicare GLP-1 Bridge ($50 per monthly fill, with conditions). Even with coverage, expect to need prior authorization.
Yes, with conditions. Basic Part D coverage excludes drugs used for weight loss, but the separate Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which runs outside your Part D plan, covers the Zepbound KwikPen for weight loss at $50 per monthly fill for Part D enrollees who meet CMS's eligibility criteria, once the prescriber gets prior authorization. If you have obstructive sleep apnea (OSA), your Part D plan may cover Zepbound (subject to its formulary and prior authorization) under the December 20, 2024 FDA approval (people with moderate-to-severe OSA can't use the Bridge). See our Zepbound Medicare guide.
Medicaid coverage varies by state. 13 states (as of January 2026) explicitly cover GLP-1 medications for obesity under fee-for-service Medicaid; GLP-1s for type 2 diabetes are covered separately. Note: Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026. The CMS BALANCE Model's Medicaid track is voluntary for states; no participating state has been confirmed.
Expect it. The insurer policies we checked (UnitedHealthcare, Cigna, Aetna) all require prior authorization when they cover Zepbound for weight loss. Insurers typically request BMI documentation, evidence of weight-related medical conditions, lifestyle program participation, and sometimes prior treatment history before approving coverage.
Many insurers classify Zepbound as a weight-loss medication, which is excluded under many pharmacy benefit designs. Effective January 1, 2026, several insurers (including Health New England for individual and small-group members, and Fallon Health's Community Care plans) dropped GLP-1 coverage for weight loss. From July 2025 to September 2026, Zepbound was nonpreferred or excluded on some of CVS Caremark's most common commercial formularies; since October 1, 2026 it is back on CVS Caremark's commercial template formularies as an additional preferred option, though plan sponsors can customize. Some plans that exclude weight loss may still cover Zepbound for sleep apnea.
Yes. If your employer self-funds its health plan (common at large companies), they have authority to add Zepbound coverage even if the insurer's standard plans exclude it. Employer surveys reported by HR Executive found about 90% of large employers covering GLP-1s plan to keep coverage in 2026. Your HR or benefits administrator can confirm your specific plan's coverage.
Sometimes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (December 20, 2024). Some plans that exclude weight-loss coverage can cover Zepbound for the OSA indication with appropriate medical documentation (sleep study confirming diagnosis); UnitedHealthcare, for example, has a separate OSA policy. Your Part D plan may cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization. This is an important alternative coverage pathway.
Insurance Coverage for Other GLP-1s
Coverage varies significantly by medication. Compare your options:
References
- Insurer prior authorization policies: UnitedHealthcare Weight Loss program (2026 P 1114-23) uhcprovider.com (PDF); Cigna Drug Coverage Policy IP0816 (Zepbound) cigna.com (PDF); Aetna Zepbound PA policy 6947-C aetna.com
- Kaiser Family Foundation / Peterson-KFF Health System Tracker. (October 2025). "2025 Employer Health Benefits Survey" and "Perspectives from Employers on GLP-1 Coverage." In 2025, 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1 drugs for weight loss. https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/
- U.S. Food and Drug Administration. (December 20, 2024). FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Kaiser Family Foundation. (2024). "Medicaid Coverage of and Spending on GLP-1s." Tracking of state Medicaid GLP-1 coverage policies. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
- Kaiser Family Foundation. (January 2025). "Medicare Advantage Prior Authorization Determinations (2023)." 81% of MA appeals succeed; we use a conservative 65%+ estimate for commercial insurance. https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2023/
- American Medical Association. (2024). "Over 80% of prior auth appeals succeed." https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- Centers for Medicare & Medicaid Services. (December 23, 2025). "CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines and Promote Healthier Living." Announcement of the BALANCE Model for GLP-1 access via negotiated pricing. https://www.cms.gov/newsroom/press-releases/cms-launches-voluntary-model-expand-access-life-changing-medicines-promote-healthier-living
- GoodRx. (December 2025). "Zepbound Medicare Coverage and Co-Pay Details." Medicare Part D out-of-pocket cap ($2,000 in 2025; $2,100 in 2026 ($2,400 in 2027)). https://www.goodrx.com/zepbound/medicare-coverage
- Leonine FOCUS. (November 2025). "Who Gets the Shot? GLP-1 Access by State." 36 states cover at least one GLP-1 through Medicaid; 13 explicitly include coverage for weight management under fee-for-service. https://www.leoninefocus.com/who-gets-the-shot-glp-1-access-by-state/
- California Department of Health Care Services. (January 2026). "Changes to GLP-1 Drug Coverage – Effective January 1, 2026." Medi-Cal restrictions on GLP-1 coverage for weight loss. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/GLP1_Changes.pdf
- Insurer notices: Health New England, "GLP-1 Medication Update" healthnewengland.org; Fallon Health, "Changes to weight loss drug coverage starting January 1, 2026" fallonhealth.org; Blue Cross Blue Shield of Massachusetts, "GLP-1 medications for obesity: coverage update" bluecrossma.com
- Massachusetts Group Insurance Commission / Mass.gov. (October 2025). "CVS Caremark decides to remove Zepbound from CVS Caremark formulary." Zepbound removed effective July 1, 2025; Wegovy preferred alternative. https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary
- HR Executive. (December 2025). "Emerging GLP-1 drugs are reshaping employers' 2026 priorities." About 90% of larger employers plan to continue covering GLP-1s; 86% of mid-market employers. https://hrexecutive.com/emerging-glp-1-drugs-are-reshaping-employers-2026-priorities/
- Mercer. (2025). "GLP-1 considerations for 2026: Your questions answered." In 2024, 44% of employers with 500+ employees covered weight loss medications; 64% of those with 20,000+ employees. https://www.mercer.com/en-us/insights/us-health-news/glp-1-considerations-for-2026-your-questions-answered/
- Employee Benefit Research Institute. (October 2025). "GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums." Simulated premium increases of 5.3% to 13.8% under real-world drug cost scenarios. https://www.ebri.org/content/glp-1-coverage-and-its-impact-on-employment-based-health-plan-premiums--a-simulation-based-analysis
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.